WO2007071839A3 - Potentialisation de l'apoptose par des anticorps monoclonaux dont la teneur en fucose est inferieure a 65 % - Google Patents

Potentialisation de l'apoptose par des anticorps monoclonaux dont la teneur en fucose est inferieure a 65 % Download PDF

Info

Publication number
WO2007071839A3
WO2007071839A3 PCT/FR2006/002767 FR2006002767W WO2007071839A3 WO 2007071839 A3 WO2007071839 A3 WO 2007071839A3 FR 2006002767 W FR2006002767 W FR 2006002767W WO 2007071839 A3 WO2007071839 A3 WO 2007071839A3
Authority
WO
WIPO (PCT)
Prior art keywords
apoptosis
potentiation
monoclonal antibodies
mla
composition
Prior art date
Application number
PCT/FR2006/002767
Other languages
English (en)
Other versions
WO2007071839A2 (fr
Inventor
Nathalie Fournier
Romeuf Christophe De
Original Assignee
Lab Francais Du Fractionnement
Nathalie Fournier
Romeuf Christophe De
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lab Francais Du Fractionnement, Nathalie Fournier, Romeuf Christophe De filed Critical Lab Francais Du Fractionnement
Priority to BRPI0619994-1A priority Critical patent/BRPI0619994A2/pt
Priority to EP06841970A priority patent/EP1969368A2/fr
Priority to AU2006328798A priority patent/AU2006328798B2/en
Priority to CA002633331A priority patent/CA2633331A1/fr
Priority to JP2008545047A priority patent/JP2009519302A/ja
Priority to US12/097,686 priority patent/US20090305228A1/en
Publication of WO2007071839A2 publication Critical patent/WO2007071839A2/fr
Publication of WO2007071839A3 publication Critical patent/WO2007071839A3/fr
Priority to IL192195A priority patent/IL192195A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)

Abstract

La présente invention se rapporte à l'utilisation d'une composition d'anticorps anti MLA-DR exprimés dans la ligne YB210, dont la teneur en fucose est inférieure à 65% pour induire in vitro l'apoptose.
PCT/FR2006/002767 2005-12-16 2006-12-15 Potentialisation de l'apoptose par des anticorps monoclonaux dont la teneur en fucose est inferieure a 65 % WO2007071839A2 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
BRPI0619994-1A BRPI0619994A2 (pt) 2005-12-16 2006-12-15 potencialização da apoptose por anticorpos monoclonais
EP06841970A EP1969368A2 (fr) 2005-12-16 2006-12-15 Potentialisation de l' apoptose par des anticorps monoclonaux
AU2006328798A AU2006328798B2 (en) 2005-12-16 2006-12-15 Potentiation of apoptosis by monoclonal antibodies
CA002633331A CA2633331A1 (fr) 2005-12-16 2006-12-15 Potentialisation de l'apoptose par des anticorps monoclonaux dont la teneur en fucose est inferieure a 65 %
JP2008545047A JP2009519302A (ja) 2005-12-16 2006-12-15 モノクローナル抗体によるアポトーシスの増強作用
US12/097,686 US20090305228A1 (en) 2005-12-16 2006-12-15 Potentiation of Apoptosis by Monoclonal Antibodies
IL192195A IL192195A0 (en) 2005-12-16 2008-06-15 Potentiation of apoptosis by monoclonal antibodies

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0512815 2005-12-16
FR0512815A FR2895086B1 (fr) 2005-12-16 2005-12-16 Potentialisation de l'apoptose par des anticorps monoclonaux

Publications (2)

Publication Number Publication Date
WO2007071839A2 WO2007071839A2 (fr) 2007-06-28
WO2007071839A3 true WO2007071839A3 (fr) 2007-08-23

Family

ID=36932747

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2006/002767 WO2007071839A2 (fr) 2005-12-16 2006-12-15 Potentialisation de l'apoptose par des anticorps monoclonaux dont la teneur en fucose est inferieure a 65 %

Country Status (11)

Country Link
US (1) US20090305228A1 (fr)
EP (1) EP1969368A2 (fr)
JP (1) JP2009519302A (fr)
KR (1) KR20080106164A (fr)
CN (1) CN101375160A (fr)
AU (1) AU2006328798B2 (fr)
BR (1) BRPI0619994A2 (fr)
CA (1) CA2633331A1 (fr)
FR (1) FR2895086B1 (fr)
IL (1) IL192195A0 (fr)
WO (1) WO2007071839A2 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999058147A1 (fr) * 1998-05-08 1999-11-18 Universite Catholique De Louvain APOPTOSE DE CELLULES TUEUSES HUMAINES NAÏVES PAR FORMATION DE LIAISONS CROISEES ENTRE LEURS MOLECULES FcγRllla ET UN ISOTYPE lgG2b DU RAT (LO-CD2a/BTI-322) OU SON ANTICORPS MONOCLONAL HUMANISE igG1
WO2001077181A2 (fr) * 2000-04-12 2001-10-18 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Anticorps monoclonaux anti-rhesus d

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5783186A (en) * 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
FR2844455B1 (fr) * 2002-09-13 2007-12-14 Lab Francais Du Fractionnement Traitement des pathologies echappant a la reponse immune par des anticorps optimises
CA2498315C (fr) * 2002-09-13 2013-01-29 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Anticorps induisant la production de cytokines
FR2844513B1 (fr) * 2002-09-13 2007-08-03 Lab Francais Du Fractionnement Anticorps pour adcc et induisant la production de cytokines.
FR2858235B1 (fr) * 2003-07-31 2006-02-17 Lab Francais Du Fractionnement Utilisation d'anticorps optimises en adcc pour traiter les patients faibles repondeurs

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999058147A1 (fr) * 1998-05-08 1999-11-18 Universite Catholique De Louvain APOPTOSE DE CELLULES TUEUSES HUMAINES NAÏVES PAR FORMATION DE LIAISONS CROISEES ENTRE LEURS MOLECULES FcγRllla ET UN ISOTYPE lgG2b DU RAT (LO-CD2a/BTI-322) OU SON ANTICORPS MONOCLONAL HUMANISE igG1
WO2001077181A2 (fr) * 2000-04-12 2001-10-18 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Anticorps monoclonaux anti-rhesus d

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BOYLE J J: "Human macrophages kill human mesangial cells by Fas-L-induced apoptosis when triggered by antibody via CD16", CLINICAL AND EXPERIMENTAL IMMUNOLOGY, vol. 137, no. 3, September 2004 (2004-09-01), pages 529 - 537, XP002397821, ISSN: 0009-9104 *
OSHIMI Y ET AL: "Necrosis and apoptosis associated with distinct Ca2+ response patterns in target cells attacked by human natural killer cells.", THE JOURNAL OF PHYSIOLOGY. 1 SEP 1996, vol. 495 ( Pt 2), 1 September 1996 (1996-09-01), pages 319 - 329, XP002398688, ISSN: 0022-3751 *
ROTHMAN R J ET AL: "Antibody-dependent cytotoxicity mediated by natural killer cells is enhanced by castanospermine-induced alterations of IgG glycosylation.", MOLECULAR IMMUNOLOGY DEC 1989, vol. 26, no. 12, December 1989 (1989-12-01), pages 1113 - 1123, XP002435543, ISSN: 0161-5890 *
SHINKAWA T ET AL: "The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,, US, vol. 278, no. 5, 31 January 2003 (2003-01-31), pages 3466 - 3473, XP002965857, ISSN: 0021-9258 *
TAKESHITA SEIICHIRO ET AL: "Intravenous immunoglobulin preparations promote apoptosis in hpopolysaccharide-stimulated neutrophils via an oxygen-dependent pathway in vitro", APMIS, vol. 113, no. 4, April 2005 (2005-04-01), pages 269 - 277, XP002397822, ISSN: 0903-4641 *

Also Published As

Publication number Publication date
JP2009519302A (ja) 2009-05-14
AU2006328798A1 (en) 2007-06-28
FR2895086A1 (fr) 2007-06-22
FR2895086B1 (fr) 2012-10-05
US20090305228A1 (en) 2009-12-10
WO2007071839A2 (fr) 2007-06-28
BRPI0619994A2 (pt) 2011-10-25
IL192195A0 (en) 2008-12-29
AU2006328798B2 (en) 2012-02-09
EP1969368A2 (fr) 2008-09-17
CN101375160A (zh) 2009-02-25
CA2633331A1 (fr) 2007-06-28
KR20080106164A (ko) 2008-12-04

Similar Documents

Publication Publication Date Title
EP1867659A4 (fr) Anticorps réactif spécifiquement vis-a-vis d'age dérivé de 3,4-dge
WO2009052400A8 (fr) Anticorps qui se lient à la ngal des mammifères et utilisations de ceux-ci
TW201129381A (en) Antibodies against human CSF-1R and uses thereof
SG10201407388XA (en) Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
HK1201860A1 (en) Antibodies to tgfbeta tgf
WO2007093627A3 (fr) Composition biocide
UA101487C2 (en) Humanized b-ly1 antibody formulation
WO2009128963A3 (fr) Anticorps monoclonaux humains à neutralisation croisée dirigés contre sars-cov et procédés d'utilisation de ces derniers
WO2009002947A3 (fr) Composés et peptides de liaison au récepteur de trail
MX2010005682A (es) Anticuerpos bivalentes, biespecificos.
MX2010005888A (es) Anticuerpos bivalentes biespecificos.
MX2010006396A (es) Anticuerpos bivalentes, biespecificos.
UA100874C2 (en) Bivalent bispecific antibodies
MX336682B (es) Anticuerpos contra csf-1r humanos y usos de los mismos.
EA200801959A1 (ru) Высокоразветвленный полипропилен
SG178886A1 (en) Humanized anti-cdcp1 antibodies
WO2008046581A3 (fr) Composés tétrahydropyrrolopyrazine substitués et leur utilisation dans des médicaments
WO2010081679A3 (fr) Anticorps dirigés contre le récepteur humain de l'érythropoïétine
WO2008005908A3 (fr) Dérivés de pyridoïmidazole
WO2008065384A3 (fr) Composés
MY149433A (en) Nutritional compositions containing punicalagins
MX2010000979A (es) Metodos y composiciones para tratar enfermedad autoinmune.
WO2008023264A3 (fr) Production de coenzyme q10 à partir de bactéries marines
WO2009103813A3 (fr) Compositions fongicides contenant du 3'-bromo-2,3,4,6'-tétraméthoxy-2'-6-diméthylbenzophénone
MY148673A (en) Cosmetic composition comprising an aluminium salt

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2008545047

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2633331

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006328798

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 5899/DELNP/2008

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2006841970

Country of ref document: EP

Ref document number: 1020087017266

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2006328798

Country of ref document: AU

Date of ref document: 20061215

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2006328798

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200680052923.5

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2006841970

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12097686

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0619994

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20080617